P
153.41
2.85 (1.89%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Palvella Therapeutics, Inc. | Mixed | Bullish |
AIStockmoo Score
-1.6
| Analyst Consensus | NA |
| Insider Activity | -5.0 |
| Price Volatility | -4.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -1.63 |
|
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company’s lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company’s patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 22.87% |
| % Held by Institutions | 47.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Montanova Capital, Llc | 30 Jun 2026 | 1,135,406 |
| Bvf Inc/Il | 30 Jun 2026 | 672,789 |
| Frontier Capital Management Co Llc | 30 Jun 2026 | 478,833 |
| Woodline Partners Lp | 30 Jun 2026 | 317,517 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| GOIN KATHLEEN | - | 151.43 | -4,302 | -651,452 |
| JENKINS GEORGE M | - | 151.01 | -27,500 | -4,151,341 |
| Aggregate Net Quantity | -31,802 | |||
| Aggregate Net Value ($) | -4,802,793 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 151.12 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GOIN KATHLEEN | Officer | 16 Sep 2026 | Automatic sell (-) | 4,302 | 151.43 | 651,452 |
| GOIN KATHLEEN | Officer | 16 Sep 2026 | Option execute | 4,302 | - | - |
| JENKINS GEORGE M | Director | 15 Sep 2026 | Automatic sell (-) | 1,777 | 151.22 | 268,718 |
| JENKINS GEORGE M | Director | 14 Sep 2026 | Automatic sell (-) | 13,352 | 151.69 | 2,025,365 |
| JENKINS GEORGE M | Director | 11 Sep 2026 | Automatic sell (-) | 12,371 | 150.13 | 1,857,258 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |